Symbols

VSTM

Verastem·NASDAQ

--(--)

VSTM fundamentals

VSTM Q4 2025 Earnings

Verastem (VSTM) released its earnings on Mar 4, 2026: revenue was 17.54M (YoY --), beat estimates; EPS was -0.5 (YoY +62.41%), beat estimates.

Revenue / YoY

17.54M

EPS / YoY

-0.5

+62.41%

Report date

Mar 4, 2026

VSTM Earnings Call Summary for Q4,2025

Commercial Success: $30.9M in CO-PACK revenue since launch, with 300+ prescribers and 60% patient co-pay program utilization.
Pipeline Progress: VS-7375 at 900mg dose shows strong safety; RAMP 301 Phase III trial on track for 2027 readout.
Financial Strength: $234M cash post-warrant exercise; LGSOC franchise to be self-sustaining by H2 2026.
Strategic Focus: Accelerate VS-7375 trials, maintain disciplined expense management, and explore non-dilutive financing.

Earnings

EPS

Revenue

Revenue & Expenses

VSTM has released its 2025 Q4 earnings report, with revenue of 17.54M, reflecting a YoY change of NaN%, and net profit of -32.92M, showing a YoY change of 49.01%. The Sankey diagram below clearly presents VSTM's revenue sources and cost distribution.

Key Indicators

Verastem (VSTM) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Verastem (VSTM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Verastem (VSTM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Verastem (VSTM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown